Used as a potent JAK2 (Janus Kinase 2) inhibitor in pharmaceutical research, particularly targeting kinases involved in inflammatory and oncogenic signaling pathways via the JAK-STAT pathway. Shows promising activity in preclinical studies and animal models for treating autoimmune diseases such as rheumatoid arthritis and psoriasis, as well as blood disorders and certain cancers like myeloproliferative neoplasms and leukemia associated with JAK2 mutations (e.g., V617F). Its structure allows for strong binding to specific enzyme targets, enhancing therapeutic potential while minimizing off-target effects, and modulating key cellular responses including cytokine signaling to reduce inflammation and abnormal cell proliferation. Also employed in structure-activity relationship (SAR) studies to develop more effective kinase inhibitors.